METHODS FOR TREATING OCULAR INFLAMMATORY DISEASES

• US 20190332516A1
• Filed: 01/02/2019
• Published: 10/31/2019
• Est. Priority Date: 03/06/2009
• Status: Active Grant

• Current Assignee: Sun Pharma Global Fze (Sun Pharmaceutical Industries Limited)
• Original Assignee: Sun Pharma Global Fze (Sun Pharmaceutical Industries Limited)
• Inventors: BOWMAN, Lyle M., HOSSEINI, Kamran
• Granted Patent: US 11,154,560 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: G06F 11/261 by simulating additional hardware, e.g. fault simulation
• CPC Class Codes: G06F 11/3013 where the computing system is an embedded system, i.e. a combination of hardware and software dedicated to perform a certain function in mobile devices, printers, automotive or aircraft systems testing or monitoring of control systems or parts thereof G05B23/02
• CPC Class Codes: G06F 11/3457 Performance evaluation by simulation
• CPC Class Codes: G06F 11/3476 Data logging G06F11/14, G06F11/2205 take precedence
• CPC Class Codes: G06F 11/3636 by tracing the execution of the program
• CPC Class Codes: G06F 11/366 using diagnostics G06F11/0703 takes precedence

Abstract

A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

Claims

1. A method of treating blepharitis comprising administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis, said active ingredient consisting essentially of a glucocorticoid, said ophthalmically acceptable vehicle comprising an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient, wherein said aqueous polymer suspension comprises a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises.

2. The method of claim 1, wherein the glucocorticoid is selected from the group consisting of hydrocortisone, cortisone acetate, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, and beclometasone, fluorometholone.

3. The method of claim 2, wherein the glucocorticoid is dexamethasone.

4. The method of claim 1, wherein the glucocorticoid is present in a range from about 0.05% and to about 0.5% by weight.

5. The method of claim 4, wherein the glucocorticoid is present in a range from about 0.08% to about 0.12% by weight.

6. The method of claim 1, wherein the glucocorticoid is present in at about 0.1% by weight.

7. The method of claim 1, wherein said ophthalmically acceptable vehicle further comprises a preservative.

8. The method of claim 6, wherein said preservative comprises benzalkonium chloride.

9. The method of claim 8, wherein said preservative is present in a range from about 0.001 to about 0.005% by weight.

10. A kit comprising:

(a) a composition comprising about 0.1% by weight dexamethasone in an ophthalmically acceptable vehicle, said ophthalmically acceptable vehicle comprising an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient, wherein said aqueous polymer suspension comprises a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises, and (b) instructions for using the composition of (a) for the treatment of blepharitis.